Overtreatment of epilepsy medications is the taking of unnecessary or excessive drug loads to control epilepsy, resulting in an inappropriate risk- efficacy balance. Overtreatment will cause serious adverse effects and waste of resources. The main reasons for overtreatment of epilepsy medications are: 1. Use of antiepileptic drugs as prophylaxis for patients at high risk for epilepsy; 2. Use of antiepileptic drugs for occasional isolated seizures with the aim of improving the long-term course of epilepsy; 3. Maintenance of one maximum tolerated dose of antiepileptic drugs by patients despite lack of individual efficacy; 4. Maintenance of multiple antiepileptic drugs by patients despite lack of individual efficacy. Strategies to avoid overtreatment are: 1. For epileptic seizures, it should be clarified whether the seizure is event-related (e.g., sleep deprivation, alcohol consumption, hypoglycemia, etc.) or caused by a medical condition, or a benign epilepsy with few seizures and only mild convulsions. For epileptic seizures caused by medical disorders, treatment should be directed at the primary cause, and long-term treatment with antiepileptic drugs is required only if the patient has recurrent convulsions and the triggering factors cannot be corrected. Status epilepticus or nonconvulsive simple partial status epilepticus with no positive evidence of brain injury and a better prognosis generally does not require overly aggressive antiepileptic drug therapy. Misdiagnosis of nonepileptic seizures often causes inappropriate antiepileptic drug therapy. 2. When first-line antiepileptic drug monotherapy is selected, the maintenance dose is initially titrated from a small dose and gradually titrated to a low dose, and no drug loading approach is taken for non-emergency treatment (e.g., status epilepticus). 3. If seizures continue, the drug may be increased to a tolerated dose; if seizures remain uncontrolled, the drug should be reduced and converted to the average dose of another first-line drug with a different pharmacologic mechanism. When the 2nd monotherapy responds well, the original drug may be slowly withdrawn. When the drug is still not controlling seizures at great doses, antiepileptic drug-induced epileptic seizures or improper drug selection should be alerted. When adding treatment, the first drug with existing adverse effects should be slowly reduced to a moderate dose, followed by the addition of another drug with a different pharmacological mechanism. The combination of two drugs appears to be more effective than monotherapy with sequential replacement of two drugs. If the combination of two drugs is not effective within 3 months, the patient should be slowly switched to monotherapy with the second drug and the addition of the new antiepileptic drug of choice should be started. 5. If monotherapy or combination therapy with 4 or 5 adequate antiepileptic drugs fails to control seizures, the likelihood of success on any AED or any combination of antiepileptic drugs is less than 5%. In such cases, the goal of treatment is simply to strike a balance between inadequate seizure control and minimal drug side effects. In conclusion, correcting the tendency to overmedicate in chronic epilepsy is not easy, and slowly reducing the drug load often provides the greatest benefit without loss of seizure control.